Abstract
BackgroundMavoglurant (AFQ056), a selective metabotropic glutamate receptor 5 (mGluR5) inhibitor, was tested for t levodopa-induced dyskinesia (LID) in patients with Parkinson’s Disease (PD). However, clinical trials showed inconsistent results regarding the efficacy of mavoglurant in treating LID in patients with Parkinson's disease (PD).MethodsA computer literature search of PubMed, Scopus, Web of science, and Cochrane CENTRAL was conducted until March 2021. We selected relevant randomized controlled trials comparing mavoglurant to placebo. Study data were extracted and pooled as mean difference (MD) in the meta-analysis model.ResultsSix RCTs were included in this meta-analysis with a total of 485 patients. Mavoglurant was not significantly superior to placebo in terms of the “off-time” (MD −0.27 h, 95% CI −0.65 to 0.11), “on time” (MD 0.29 h, 95% CI −0.09 to 0.66), Lang-Fahn activities of daily living dyskinesia scale (MD −0.95, 95% CI −1.98 to 0.07), UPDRS-III (MD −0.51, 95% CI −1.66 to 0.65), or UPDRS-IV (MD −0.41, 95% CI −0.85 to 0.03). However, the pooled modified abnormal involuntary movement scale favored the mavoglurant group than the placebo group (MD −2.53, 95% CI −4.23 to −0.82).ConclusionsThis meta-analysis provides level one evidence that mavoglurant is not effective in treating the LID in patients with PD.
Highlights
Parkinson's disease is a common neurological disorder affecting about 1–3% above 60 years population [1]
We evaluated the safety and efficacy of mavoglurant compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s Disease (PD) patients using data from randomized controlled trials pooled in the context of meta-analysis
PD patients remained on the levodopa treatment during the study period
Summary
Parkinson's disease is a common neurological disorder affecting about 1–3% above 60 years population [1]. The loss of dopaminergic neurons and the formation of Lewy bodies are Sharkia, Zagazig 44523, Egypt 3 School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK 4 Faculty of Medicine, Al-Azhar University, Cairo, Egypt 5 Faculty of Medicine, Suez Canal University, Ismailia, Egypt 6 Faculty of Medicine, Al-Azhar University of Damietta, Damietta, Egypt 7 Neuropsychiatry Department, Omr Shahin Mental Hospital, Cairo, Egypt the cardinal pathological features of PD. A precursor of dopamine, is considered as the standard of care for patients with early PD. Mavoglurant (AFQ056), a selective metabotropic glutamate receptor 5 (mGluR5) inhibitor, was tested for t levodopa-induced dyskinesia (LID) in patients with Parkinson’s Disease (PD). Clinical trials showed inconsistent results regarding the efficacy of mavoglurant in treating LID in patients with Parkinson's disease (PD). Study data were extracted and pooled as mean difference (MD) in the meta-analysis model
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
